Program
QLS2416
A development code. Also written as “QLS2416 Injection”.
Its studies are mostly in Lupus Erythematosus, Systemic, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 11 open or running | phase 1since Oct 23, 2026 | Oct 23, 2026 | Jun 2029phase 1 · NCT07906145 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2026First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07906145 · 76 planned
Ahead
- Jun 2029Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07906145
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07906145Lupus Erythematosus, Systemic | 1 | Not yet recruiting | Jun 2029 | 76 |
How it is read
Names in the registry
- “QLS2416 Injection”, 1 entry
Codes read as this program: QLS2416.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.